What Are The Major Factors Driving Retinal Biologics Market Growth?
The Retinal Biologics Market is experiencing a surge in demand, fueled by advancements in eye disease treatments and a growing emphasis on vision health. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the market is currently valued at an impressive US$22.25 billion in 2022. Looking ahead, the market is projected to witness a remarkable Compound Annual Growth Rate (CAGR) of 11.1% over the next six years. This translates to a staggering market valuation of US$41.92 billion by 2028, highlighting the significant potential of retinal biologics in revolutionizing eye care.
The remarkable expansion of the Global Retinal Biologics sector is fueled by advancements in technology, innovative research, and a growing demand for cutting-edge treatments. As the industry continues to evolve, it presents unprecedented opportunities for stakeholders, investors, and healthcare professionals alike.
Key Retinal Biologics Market Insights:
Rising Prevalence of Diabetes-related Eye Disorders and Age-related Macular Degeneration (AMD) The prevalence of diabetes-related eye disorders and age-related macular degeneration is on the rise, underscoring the growing need for innovative solutions within the Retinal Biologics Industry.
Substantial Investment in R&D for Biologics in Retinal Disorders The industry is witnessing a significant influx of research and development resources, aimed at advancing biologics for both infectious and non-infectious retinal disorders. This investment underscores the commitment to addressing unmet medical needs.
Emergence of Specific Biologic Molecules as Therapeutic Targets Specific biologic molecules are gaining prominence as highly promising therapeutic targets, offering new hope for patients with retinal conditions.
Gene Therapy as a Solution for Monogenic Retinal Illnesses With a growing number of monogenic retinal illnesses, gene therapy is emerging as a pivotal component of the Retinal Biologics Market, presenting innovative solutions for these challenging conditions.
Request a Sample Copy of This Report Now.
https://www.futuremarketinsigh....ts.com/reports/sampl
Retinal Biologics Distribution in Specialty Clinics and Hospitals Prominent
Retinal Biologics manufacturers offer their goods through institutional and retail distribution channels. According to the FMI report, institutional sales in the Retinal Biologics Industry, where Retinal Biologics are supplied in speciality clinics and hospitals, will generate higher revenues. In 2018, hospital sales accounted for more than 35% of market revenue.
According to the report, retail sales of Retinal Biologics will generate comparable revenues to hospital sales and will expand at an 11.9% annual rate in 2019. Retail distribution takes place through retail pharmacies and mail-order pharmacies, with retail pharmacies generating more money than their counterparts in the future years.
Penetration in North America Higher, APEJ’s Attractiveness to Increase
North America continues to be the market leader in Retinal Biologics revenue. According to FMI estimates, North America accounted for more than 46% of global Retinal Biologics Industry revenues in 2018. Revenues in North America are predicted to expand 10.4% year on year in 2019 due to an increase in the prevalence of retinal illnesses, continuous growth in the healthcare infrastructure, and a favourable reimbursement scenario.
Europe accounted for about one-fourth of the Retinal Biologics market, with Western European countries such as Germany, the United Kingdom, France, Italy, and Spain accounting for the majority of demand penetration. The APEJ Retinal Biologics Industry is predicted to grow at an 11% annual rate in 2019, with China and India remaining the most lucrative areas.
Retinal Biologics Find Prominent Use in Macular Degeneration Treatment
The study opines that over 35% of the Retinal Biologics revenues were consolidated in the treatment of macular degeneration. The highest revenue growth of 12.3% is also expected in macular degeneration as compared to other indications where Retinal Biologics are used in 2019.
Macular degeneration (MD) remains the leading cause of vision loss wherein it affects over 10 million Americans, the prevalence is higher than the combined incidences of cataracts and glaucoma, as per the American Macular Degeneration Foundation (AMDF). As macular degeneration mainly affects people aged 50 years or more, with the ageing population, the prevalence of MD continues to rise despite improved treatment options.
Key Players Covered In The Retinal Biologics Market:
Spark Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.
AbbVie Inc.
Amgen Inc.
Novartis Pharma AG
MeiraGTx Limited
Oxurion NV
Santen Pharmaceutical Co., Ltd.
Bayer AG
Bausch Health Companies Inc.
Merck & Co., Inc.
Level Up Your Market Understanding – Purchase Now!
https://www.futuremarketinsights.com/checkout/8663
Key Segments of Global Retinal Biologics Industry Survey
Retinal Biologics Market by Drug Class:
VEGF-A Antagonists
TNF-α Inhibitors
Retinal Biologics Market by Indication:
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy
Uveitis
Others
Retinal Biologics Market by Distribution Channel:
Institutional Sales
Retail Pharmacies
Mail Order Pharmacies
Retail Sales
1 (877) 773-1002